Literature DB >> 31884632

Parthanatos as a Cell Death Pathway Underlying Retinal Disease.

Scott H Greenwald1, Eric A Pierce2.   

Abstract

Parthanatos is a programmed cell death pathway mediated by the effects of pathogenically high levels of poly(ADP-ribose) polymerase 1 (PARP1) activity. This process underlies a broad range of diseases affecting many tissues and organs across the body, including the retina. This chapter reviews mechanisms that are currently understood to drive parthanatos in the context of retinal diseases associated with this form of cell death. Toxicity of upregulated poly(ADP-ribose) (PAR) content, NAD+ and ATP depletion, translocation of apoptosis-inducing factor (AIF) to the nucleus, and loss of glycolytic function are discussed. Since therapies that preserve vulnerable cells remain elusive for the vast majority of retinal diseases, pharmacologically blocking parthanatos may be an effective treatment strategy for cases in which this process contributes to pathogenesis.

Entities:  

Keywords:  Apoptosis-inducing factor; Bioenergetics; NAD+; PAR; PARP1; Parthanatos; Programmed cell death

Mesh:

Substances:

Year:  2019        PMID: 31884632      PMCID: PMC8011836          DOI: 10.1007/978-3-030-27378-1_53

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  40 in total

Review 1.  Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions.

Authors:  D D'Amours; S Desnoyers; I D'Silva; G G Poirier
Journal:  Biochem J       Date:  1999-09-01       Impact factor: 3.857

2.  Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis.

Authors:  Shaida A Andrabi; George K E Umanah; Calvin Chang; Daniel A Stevens; Senthilkumar S Karuppagounder; Jean-Philippe Gagné; Guy G Poirier; Valina L Dawson; Ted M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-01       Impact factor: 11.205

Review 3.  Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal.

Authors:  Mi Young Kim; Tong Zhang; W Lee Kraus
Journal:  Genes Dev       Date:  2005-09-01       Impact factor: 11.361

Review 4.  The PARP superfamily.

Authors:  Jean-Christophe Amé; Catherine Spenlehauer; Gilbert de Murcia
Journal:  Bioessays       Date:  2004-08       Impact factor: 4.345

5.  Noncovalent interactions of poly(adenosine diphosphate ribose) with histones.

Authors:  P L Panzeter; C A Realini; F R Althaus
Journal:  Biochemistry       Date:  1992-02-11       Impact factor: 3.162

Review 6.  Roles of NAD (+) , PARP-1, and Sirtuins in Cell Death, Ischemic Brain Injury, and Synchrotron Radiation X-Ray-Induced Tissue Injury.

Authors:  Weihai Ying
Journal:  Scientifica (Cairo)       Date:  2013-12-10

7.  Identification of a common non-apoptotic cell death mechanism in hereditary retinal degeneration.

Authors:  Blanca Arango-Gonzalez; Dragana Trifunović; Ayse Sahaboglu; Katharina Kranz; Stylianos Michalakis; Pietro Farinelli; Susanne Koch; Fred Koch; Sandra Cottet; Ulrike Janssen-Bienhold; Karin Dedek; Martin Biel; Eberhart Zrenner; Thomas Euler; Per Ekström; Marius Ueffing; François Paquet-Durand
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

8.  AIF-independent parthanatos in the pathogenesis of dry age-related macular degeneration.

Authors:  Ki-Hong Jang; Yun-Ju Do; Dongwon Son; Eunji Son; Jun-Sub Choi; Eunhee Kim
Journal:  Cell Death Dis       Date:  2017-01-05       Impact factor: 8.469

9.  NMNAT1 mutations cause Leber congenital amaurosis.

Authors:  Marni J Falk; Qi Zhang; Eiko Nakamaru-Ogiso; Chitra Kannabiran; Zoe Fonseca-Kelly; Christina Chakarova; Isabelle Audo; Donna S Mackay; Christina Zeitz; Arundhati Dev Borman; Magdalena Staniszewska; Rachna Shukla; Lakshmi Palavalli; Saddek Mohand-Said; Naushin H Waseem; Subhadra Jalali; Juan C Perin; Emily Place; Julian Ostrovsky; Rui Xiao; Shomi S Bhattacharya; Mark Consugar; Andrew R Webster; José-Alain Sahel; Anthony T Moore; Eliot L Berson; Qin Liu; Xiaowu Gai; Eric A Pierce
Journal:  Nat Genet       Date:  2012-07-29       Impact factor: 38.330

Review 10.  Cell Death Pathways: a Novel Therapeutic Approach for Neuroscientists.

Authors:  G Morris; A J Walker; M Berk; M Maes; B K Puri
Journal:  Mol Neurobiol       Date:  2017-10-19       Impact factor: 5.590

View more
  6 in total

Review 1.  Molecular Mechanisms of Parthanatos and Its Role in Diverse Diseases.

Authors:  Ping Huang; Guangwei Chen; Weifeng Jin; Kunjun Mao; Haitong Wan; Yu He
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

Review 2.  Inherited Retinal Dystrophies: Role of Oxidative Stress and Inflammation in Their Physiopathology and Therapeutic Implications.

Authors:  Isabel Pinilla; Victoria Maneu; Laura Campello; Laura Fernández-Sánchez; Natalia Martínez-Gil; Oksana Kutsyr; Xavier Sánchez-Sáez; Carla Sánchez-Castillo; Pedro Lax; Nicolás Cuenca
Journal:  Antioxidants (Basel)       Date:  2022-05-30

3.  Therapeutic Properties of Ayahuasca Components in Ischemia/Reperfusion Injury of the Eye.

Authors:  Anna Szilágyi; Barbara Takács; Réka Szekeres; Vera Tarjányi; Mariann Bombicz; Dániel Priksz; Attila Kovács; Béla Juhász; Ede Frecska; Zoltán Szilvássy; Balázs Varga
Journal:  Biomedicines       Date:  2022-04-26

4.  A novel predicted ADP-ribosyltransferase-like family conserved in eukaryotic evolution.

Authors:  Zbigniew Wyżewski; Marcin Gradowski; Marianna Krysińska; Małgorzata Dudkiewicz; Krzysztof Pawłowski
Journal:  PeerJ       Date:  2021-03-10       Impact factor: 2.984

5.  Gene Therapy Preserves Retinal Structure and Function in a Mouse Model of NMNAT1-Associated Retinal Degeneration.

Authors:  Scott H Greenwald; Emily E Brown; Michael J Scandura; Erin Hennessey; Raymond Farmer; Basil S Pawlyk; Ru Xiao; Luk H Vandenberghe; Eric A Pierce
Journal:  Mol Ther Methods Clin Dev       Date:  2020-07-09       Impact factor: 6.698

Review 6.  Mitochondria Related Cell Death Modalities and Disease.

Authors:  Chuwen Tian; Yifan Liu; Zhuoshu Li; Ping Zhu; Mingyi Zhao
Journal:  Front Cell Dev Biol       Date:  2022-03-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.